Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 29c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($1.43), $0.29 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $3.76 million versus the consensus estimate of $3.94 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• H.B. Fuller (FUL) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY26 EPS Guidance
• NeoVolta Inc. (NEOV) Misses Q3 EPS by 17c